FDA Accepts sNDA for At-Home IGALMI® Use, Sets November PDUFA Date

summarizeSummary

BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application for at-home use of IGALMI® for agitation, setting a PDUFA target action date of November 14, 2026.

check_boxKey Events

• FDA Accepts sNDA for At-Home Use

  The U.S. Food and Drug Administration has accepted BioXcel Therapeutics' supplemental New Drug Application (sNDA) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI®.

• PDUFA Target Action Date Set

  The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026, for the sNDA review.

• Follows Prior Submission

  This acceptance follows the company's initial submission of the sNDA on January 20, 2026, and provides a critical update on its regulatory progress.

auto_awesomeAnalysis

This FDA acceptance is a crucial positive development for BioXcel Therapeutics, especially following recent disclosures of substantial doubt about its ability to continue as a going concern. Expanding IGALMI®'s label to include at-home use could significantly increase its market potential and revenue, providing a potential pathway to address the company's financial challenges. The assigned PDUFA date provides a clear timeline for a potential approval decision, which will be a key catalyst for the company's future.